Gamma Knife Trial Offers New Hope for Trigeminal Neuralgia Pain Relief | University of Alberta

A clinical trial underway at the University of Alberta Hospital is offering a potential new path forward for individuals grappling with trigeminal neuralgia, a condition often described as one of the most painful known to medicine. The trial is investigating whether delivering Gamma Knife stereotactic radiosurgery – a non-invasive radiation therapy – much earlier in the disease process can provide more lasting relief than current treatment protocols. This approach, termed “ultra-early” Gamma Knife treatment, aims to intervene before patients become reliant on medications that can have significant side effects and often lose effectiveness over time.

Trigeminal neuralgia (TN) affects the trigeminal nerve, responsible for sensation in the face. The condition causes episodes of intense, stabbing, or electric shock-like pain, often triggered by everyday activities like eating, speaking, or even a gentle breeze. Sometimes referred to as the “suicide disease” due to the debilitating nature of the pain, TN impacts approximately 700 people each year in Alberta alone. The Trigeminal Neuralgia Association provides support and information for those affected.

Currently, the first line of defense against TN is typically medication, specifically anti-seizure drugs like carbamazepine. While effective initially, these medications come with a range of potential side effects, including blurry vision, imbalance, and allergic reactions. Crucially, they often stop working for about half of those who take them, leading patients to seek alternative treatments. Until recently, Gamma Knife radiation was generally reserved as a last resort, offered only after medications had failed.

The Promise of Earlier Intervention

The University of Alberta trial, led by Tejas Sankar, associate professor of surgery and neurosurgery research director, is based on growing evidence suggesting that the timing of Gamma Knife treatment is critical. “We treat trigeminal neuralgia by giving a pretty high dose of radiation to the trigeminal nerve on the affected side, but the longer you wait before you offer Gamma Knife, the less likely This proves to lead to long-term remission of the disease,” explains Sankar. This trial seeks to determine if intervening earlier – before patients become medically refractory to medication – can improve outcomes.

The study is recruiting 80 patients from across the province. Participants will be randomly assigned to receive either standard medication management or “ultra-early” Gamma Knife surgery at the Scott and Brown Families Gamma Knife Centre, the only facility of its kind in Alberta. Patients in the medication group will have the option to pursue Gamma Knife treatment later if their pain persists. The trial is designed as a non-inferiority study, meaning it aims to demonstrate that ultra-early Gamma Knife is at least as good as, and potentially better than, the current standard of care.

Brain Changes and the Rationale for Early Treatment

The rationale behind this approach stems from recent research conducted by Sankar’s team using functional MRI. This research indicates that living with chronic trigeminal neuralgia actually alters brain structure, and function. “What we found was – and this shouldn’t come as too much of a surprise – the longer you have this facial pain condition, the more lasting changes occur in the brain both structurally and functionally,” Sankar says. By intervening early with Gamma Knife, the researchers hope to prevent these changes from becoming permanent, potentially leading to more durable pain relief.

Gamma Knife stereotactic radiosurgery delivers a highly focused beam of radiation to the trigeminal nerve, disrupting its ability to transmit pain signals. It’s a non-invasive procedure, meaning it doesn’t require any incisions. While it’s generally considered safe, potential side effects can include temporary facial numbness or tingling. A recent study published in PubMed highlights the safety and efficacy of Gamma Knife in medically refractory TN, suggesting earlier intervention (within 3 years of pain onset) leads to improved long-term outcomes.

Understanding the Trial Design and Goals

The current trial, registered as NCT06949436, is a phase II study, meaning it’s designed to assess the feasibility and potential benefit of ultra-early Gamma Knife treatment. The primary endpoint of the study is to evaluate whether earlier intervention yields superior long-term pain relief compared to ongoing medical management. Researchers will similarly be monitoring for treatment-related adverse events. The study employs a randomized, controlled design, with participants assigned to either the intervention (Gamma Knife) or control (medication) arm. Crossover from the control arm to the intervention arm is permitted, allowing all participants to potentially benefit from Gamma Knife treatment if needed.

It’s essential to note that this trial is focused on patients who have recently been diagnosed with trigeminal neuralgia – within two years of diagnosis – and have not yet experienced treatment failure with medication. This specific patient population is crucial, as the researchers believe that intervening before the brain undergoes significant changes may maximize the potential benefits of Gamma Knife treatment.

What Comes Next: Implications for Trigeminal Neuralgia Care

The results of this trial are eagerly awaited by both clinicians and patients. If successful, the findings could lead to a shift in the standard of care for trigeminal neuralgia, with earlier consideration of Gamma Knife treatment for appropriate candidates. This could potentially reduce the reliance on long-term medication, minimize side effects, and improve the quality of life for individuals living with this debilitating condition. Further research, including larger phase III trials, may be necessary to confirm these findings and establish definitive guidelines for the use of ultra-early Gamma Knife treatment. The team also plans to continue investigating the underlying brain changes associated with chronic pain, which could lead to the development of even more targeted and effective therapies.